Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of the PRAISE -IR ("Phase 2 Study of Personalized r-ATG (Rabbit Anti-thymocyte Globulin) Dosing to Improve Survival Through Enhanced Immune Reconstitution in Pediatric and Adult Patients Undergoing Ex-vivo CD34-Selected Allogeneic-HCT (Hematopoietic Cell Transplantation) ", NCT04872595) Study Population With CIBMTR Controls

NCT07717164 is registered in ClinicalTrials.gov with Miltenyi Biomedicine GmbH as lead sponsor.

NCT NCT07717164
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07717164 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of the PRAISE -IR ("Phase 2 Study of Personalized r-ATG (Rabbit Anti-thymocyte Globulin) Dosing to Improve Survival Through Enhanced Immune Reconstitution in Pediatric and Adult Patients Undergoing Ex-vivo CD34-Selected Allogeneic-HCT (Hematopoietic Cell Transplantation) ", NCT04872595) Study Population With CIBMTR Controls
Lead sponsor
Miltenyi Biomedicine GmbH
Phase
Observational
Overall status
Not yet recruiting
Start date
July 31, 2026
Completion date
September 30, 2026
Enrollment
51 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

all (acute b-lymphoblastic leukemia), aml (acute myeloid leukemia), mds (myelodysplastic syndrome)